Skip to main content
EMBO Molecular Medicine logoLink to EMBO Molecular Medicine
. 2013 Feb 4;5(2):326. doi: 10.1002/emmm.201390002

Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival

Jenny S Henkel, David R Beers, Shixiang Wen, Andreana L Rivera, Karen M Toennis, Joan E Appel, Weihua Zhao, Dan H Moore, Suzanne Z Powell, Stanley H Appel
PMCID: PMC3569646

Erratum to Jenny S. Henkel, David R. Beers, Shixiang Wen, Andreana L. Rivera, Karen M. Toennis, Joan E. Appel, Weihua Zhao, Dan H. Moore, Suzanne Z. Powell and Stanley H. Appel (2013) Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med 5 (1) DOI: 10.1002/emmm.201201544

The phrase “change in AALS score ÷ change in time” appeared as “change in AALS score, change in time”. This error occurred on pages 2, 10 and 14. The correct sentences are printed below.

Page 2

However, differences were noted when the patients were separated and grouped based on their rate of disease progression at the time of blood collection [rate was determined as the change in AALS score ÷ change in time (months), comparing the initial clinical evaluation with the evaluation performed at the time of blood collection].

Page 10

To evaluate whether early FoxP3 levels could be used to predict future progression rates, the mRNA levels in leukocytes from the 102 patients obtained early in disease were compared with their rate of progression at the end of the evaluation period [rate was determined as the change in AALS score ÷ change in time (months), comparing the initial evaluation with the evaluation at the end of the 3.5-year follow-up period].

Page 14

Rate was determined as the change in AALS score ÷ change in time, comparing the initial evaluation with the evaluation at the time of collection or with the evaluation at the end of analysis.


Articles from EMBO Molecular Medicine are provided here courtesy of Nature Publishing Group

RESOURCES